Postprandial glycaemic and insulinaemic responses in adults after consumption of dairy desserts and pound cakes containing short-chain fructo-oligosaccharides used to replace sugars

Abstract

The present studies aimed to evaluate the glycaemic and insulinaemic responses, in healthy adults, to short-chain fructo-oligosaccharides (scFOS) from sucrose used to replace sugars in foods. Two study populations aged 18–50 years were recruited and they consumed dairy desserts or pound cakes containing either standard sugar content or scFOS to replace 30 % of the sugar content. For each study, the two products were tested once under a double-blind and cross-over design with at least 7 d between the two tests. Glucose and insulin were measured using standard methods in blood samples collected with a venous catheter for 120 min during a kinetic test. For the dairy desserts, replacing 30 % of the sugars with scFOS significantly reduced postprandial glycaemic (AUC0–120 min; P = 0·020) and insulinaemic (AUC0–120 min; P = 0·003) responses. For the pound cakes, the glycaemic response was not altered (AUC0–120 min; P = 0·322) while the insulinaemic response tended to be lower (AUC0–120 min; P = 0·067). This study showed that scFOS can be used to replace sugars with the benefit of lowering the postprandial glycaemic response without increasing the insulinaemic response. The effect might be modulated by other parameters (e.g. fat content) of the food matrices.

Gastrointestinal Tolerance of Short-Chain Fructo-Oligosaccharides from Sugar Beet: An Observational, Connected, Dose-Ranging Study in Healthy Volunteers

“…They are frequently used in a series of food and beverages, for fibre enrichment, which is nutritionally relevant given the low intake of fibre in some countries. They can also contribute to reducing food sugar content and energy [ 9 ]. The effects of scFOS consumption have been extensively studied in healthy adults, showing they are selectively fermented by some bacteria, especially Bifidobacteria, in a dose–response manner for doses ranging from 2.5 to 20 g/day.…”

Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial

“…Being unavailable carbohydrates, scFOS do not raise blood glucose. Thus, replacing available-carbohydrate (avCHO) with scFOS in foods reduces acute glycemic responses (Respondek et al, 2014;Lecerf et al, 2015).…”